Free Trial

SIGA Technologies (SIGA) Competitors

$7.48
+0.04 (+0.54%)
(As of 05/31/2024 ET)

SIGA vs. FLXN, ORGO, EBS, ETNB, GERN, VERA, AMPH, AGIO, AMRX, and RCKT

Should you be buying SIGA Technologies stock or one of its competitors? The main competitors of SIGA Technologies include Flexion Therapeutics (FLXN), Organogenesis (ORGO), Emergent BioSolutions (EBS), 89bio (ETNB), Geron (GERN), Vera Therapeutics (VERA), Amphastar Pharmaceuticals (AMPH), Agios Pharmaceuticals (AGIO), Amneal Pharmaceuticals (AMRX), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "medical" sector.

SIGA Technologies vs.

Flexion Therapeutics (NASDAQ:FLXN) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations, risk and community ranking.

SIGA Technologies has higher revenue and earnings than Flexion Therapeutics. Flexion Therapeutics is trading at a lower price-to-earnings ratio than SIGA Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flexion Therapeutics$85.55M5.36-$113.71M-$2.01-4.54
SIGA Technologies$139.92M3.80$68.07M$1.106.80

Flexion Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flexion Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
SIGA Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Flexion Therapeutics received 567 more outperform votes than SIGA Technologies when rated by MarketBeat users. Likewise, 64.93% of users gave Flexion Therapeutics an outperform vote while only 23.81% of users gave SIGA Technologies an outperform vote.

CompanyUnderperformOutperform
Flexion TherapeuticsOutperform Votes
572
64.93%
Underperform Votes
309
35.07%
SIGA TechnologiesOutperform Votes
5
23.81%
Underperform Votes
16
76.19%

SIGA Technologies has a net margin of 50.48% compared to SIGA Technologies' net margin of -100.32%. Flexion Therapeutics' return on equity of 51.97% beat SIGA Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Flexion Therapeutics-100.32% N/A -44.26%
SIGA Technologies 50.48%51.97%39.51%

90.0% of Flexion Therapeutics shares are held by institutional investors. Comparatively, 55.4% of SIGA Technologies shares are held by institutional investors. 9.1% of Flexion Therapeutics shares are held by company insiders. Comparatively, 1.5% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, SIGA Technologies had 9 more articles in the media than Flexion Therapeutics. MarketBeat recorded 9 mentions for SIGA Technologies and 0 mentions for Flexion Therapeutics. Flexion Therapeutics' average media sentiment score of 0.89 beat SIGA Technologies' score of 0.00 indicating that SIGA Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Flexion Therapeutics Neutral
SIGA Technologies Positive

Summary

SIGA Technologies beats Flexion Therapeutics on 9 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SIGA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SIGA vs. The Competition

MetricSIGA TechnologiesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$531.98M$6.72B$5.11B$7.97B
Dividend YieldN/A2.68%2.75%4.00%
P/E Ratio6.8010.98120.3615.18
Price / Sales3.80407.182,428.4593.40
Price / Cash7.7132.8835.0431.51
Price / Book3.226.085.524.59
Net Income$68.07M$138.60M$105.88M$213.90M
7 Day Performance0.27%3.29%1.13%0.87%
1 Month Performance-19.70%1.09%1.42%3.60%
1 Year Performance36.50%-1.29%4.04%7.91%

SIGA Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FLXN
Flexion Therapeutics
0 of 5 stars
$9.12
flat
N/AN/A$458.93M$85.55M-4.54257
ORGO
Organogenesis
3.8631 of 5 stars
$2.75
+0.7%
$4.83
+75.8%
-24.2%$364.57M$433.14M68.77862Short Interest ↑
Gap Down
EBS
Emergent BioSolutions
3.2624 of 5 stars
$5.70
+12.0%
$5.00
-12.3%
-33.2%$298.68M$1.05B-0.521,600Short Interest ↓
ETNB
89bio
3.1882 of 5 stars
$7.90
+1.5%
$28.14
+256.2%
-56.7%$777.20MN/A-3.9370Short Interest ↓
Positive News
GERN
Geron
3.5775 of 5 stars
$3.55
+2.3%
$6.10
+71.8%
+8.6%$2.11B$240,000.00-10.14141Positive News
VERA
Vera Therapeutics
1.2321 of 5 stars
$37.99
+2.8%
$36.71
-3.4%
+355.0%$2.08BN/A-18.5351Analyst Forecast
AMPH
Amphastar Pharmaceuticals
4.9862 of 5 stars
$42.33
+0.4%
$66.00
+55.9%
-4.6%$2.07B$644.40M14.651,761Short Interest ↓
AGIO
Agios Pharmaceuticals
1.9308 of 5 stars
$36.34
-3.2%
$35.00
-3.7%
+43.8%$2.06B$26.82M-5.75383Analyst Upgrade
Short Interest ↓
Analyst Revision
AMRX
Amneal Pharmaceuticals
1.5148 of 5 stars
$6.68
-1.5%
$8.25
+23.5%
+185.5%$2.06B$2.39B-11.937,700Short Interest ↑
Positive News
RCKT
Rocket Pharmaceuticals
3.8927 of 5 stars
$21.32
-0.6%
$52.13
+144.5%
+1.9%$1.94BN/A-7.43268

Related Companies and Tools

This page (NASDAQ:SIGA) was last updated on 6/1/2024 by MarketBeat.com Staff

From Our Partners